301263 泰恩康
已收盘 08-20 15:00:00
资讯
新帖
简况
泰恩康最新公告：全资子公司注射用顺铂聚合物胶束获临床试验批准
证券之星 · 08-20 17:55
泰恩康最新公告：全资子公司注射用顺铂聚合物胶束获临床试验批准
8月19日泰恩康跌5.02%，前海开源优质龙头6个月持有混合A基金重仓该股
证券之星 · 08-19 17:16
8月19日泰恩康跌5.02%，前海开源优质龙头6个月持有混合A基金重仓该股
泰恩康H1净利降9成 A股募11.8亿国泰海通保荐拟发可转债
中金财经 · 08-19 11:32
泰恩康H1净利降9成 A股募11.8亿国泰海通保荐拟发可转债
【机构调研记录】申万菱信基金调研泰恩康、盛美上海等3只个股（附名单）
证券之星 · 08-19 08:14
【机构调研记录】申万菱信基金调研泰恩康、盛美上海等3只个股（附名单）
泰恩康：华创证券、国泰海通华源证券等多家机构于8月18日调研我司
证券之星 · 08-18 17:40
泰恩康：华创证券、国泰海通华源证券等多家机构于8月18日调研我司
泰恩康(301263)6月30日股东户数1.47万户，较上期增加12.93%
证券之星 · 08-18 17:31
泰恩康(301263)6月30日股东户数1.47万户，较上期增加12.93%
泰恩康：公司正处于新旧动能转换的业绩拐点期
证券之星 · 08-18 16:54
泰恩康：公司正处于新旧动能转换的业绩拐点期
图解泰恩康中报：第二季度单季净利润同比下降548.88%
证券之星 · 08-18
图解泰恩康中报：第二季度单季净利润同比下降548.88%
泰恩康：签署战略合作协议获MSCohi-O镜片项目独家商业推广权益
格隆汇 · 08-17
泰恩康：签署战略合作协议获MSCohi-O镜片项目独家商业推广权益
泰恩康（301263）披露全资子公司巴瑞替尼片中选第十二批国家药品集采，8月10日股价上涨1.64%
证券之星 · 08-10
泰恩康（301263）披露全资子公司巴瑞替尼片中选第十二批国家药品集采，8月10日股价上涨1.64%
股市必读：泰恩康新发布《关于全资子公司部分药品中选国家药品集中采购的公告》
证券之星 · 08-10
股市必读：泰恩康新发布《关于全资子公司部分药品中选国家药品集中采购的公告》
泰恩康：全资子公司巴瑞替尼片中选第十二批国家药品集采
格隆汇 · 08-07
泰恩康：全资子公司巴瑞替尼片中选第十二批国家药品集采
8月7日泰恩康涨6.31%，前海开源优质龙头6个月持有混合A基金重仓该股
证券之星 · 08-07
8月7日泰恩康涨6.31%，前海开源优质龙头6个月持有混合A基金重仓该股
股市必读：泰恩康新发布《关于回购公司股份的进展公告》
证券之星 · 08-04
股市必读：泰恩康新发布《关于回购公司股份的进展公告》
7月17日泰恩康跌11.14%，大成积极成长混合A基金重仓该股
证券之星 · 07-17
7月17日泰恩康跌11.14%，大成积极成长混合A基金重仓该股
股市必读：泰恩康（301263）7月16日董秘有最新回复
证券之星 · 07-17
股市必读：泰恩康（301263）7月16日董秘有最新回复
7月15日泰恩康涨6.25%，大成积极成长混合A基金重仓该股
证券之星 · 07-15
7月15日泰恩康涨6.25%，大成积极成长混合A基金重仓该股
泰恩康（301263）披露控股股东部分股份解除质押公告，7月6日股价下跌1.59%
证券之星 · 07-06
泰恩康（301263）披露控股股东部分股份解除质押公告，7月6日股价下跌1.59%
7月1日泰恩康涨5.32%，大成积极成长混合A基金重仓该股
证券之星 · 07-01
7月1日泰恩康涨5.32%，大成积极成长混合A基金重仓该股
泰恩康（301263）披露控股股东部分股份质押公告，6月30日股价下跌3.94%
证券之星 · 06-30
泰恩康（301263）披露控股股东部分股份质押公告，6月30日股价下跌3.94%
加载更多
公司概况
公司名称：
广东泰恩康医药股份有限公司
所属行业：
批发业
上市日期：
2022-03-29
主营业务：
广东泰恩康医药股份有限公司的主营业务是代理运营及研发、生产、销售医药产品、医疗器械、卫生材料并提供医药技术服务与技术转让等。公司的主要产品是盐酸达泊西汀片、他达拉非片、枸橼酸西地那非口崩片、和胃整肠丸、沃丽汀、风油精、六味地黄丸、藿香正气丸、奥硝唑注射液。
发行价格：
19.93
{"stockData":{"symbol":"301263","market":"SZ","secType":"STK","nameCN":"泰恩康","latestPrice":19.83,"timestamp":1787209437000,"preClose":19.67,"halted":0,"volume":6023878,"delay":0,"changeRate":0.0081,"floatShares":364000000,"shares":511000000,"eps":-0.0093,"marketStatus":"已收盘","change":0.16,"latestTime":"08-20 15:00:00","open":20,"high":20.76,"low":19.7,"amount":121000000,"amplitude":0.0539,"askPrice":19.87,"askSize":6,"bidPrice":19.83,"bidSize":412,"shortable":0,"etf":0,"ttmEps":-0.0093,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787275800000},"marketStatusCode":5,"adr":0,"adjPreClose":19.67,"symbolType":"stock","openAndCloseTimeList":[[1787189400000,1787196600000],[1787202000000,1787209200000]],"highLimit":21.64,"lowLimit":17.7,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":510597000,"isCdr":false,"pbRate":6.09,"roa":"--","roe":"0.22%","epsLYR":0.07,"committee":0.385354,"marketValue":10125000000,"turnoverRate":0.0165,"status":0,"floatMarketCap":7224000000},"requestUrl":"/m/hq/s/301263","defaultTab":"news","newsList":[{"id":"2660288738","title":"泰恩康最新公告：全资子公司注射用顺铂聚合物胶束获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2660288738","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660288738?lang=zh_cn&edition=full","pubTime":"2026-08-20 17:55","pubTimestamp":1787219730,"startTime":"0","endTime":"0","summary":"泰恩康(301263.SZ)公告称，公司全资子公司华铂凯盛收到国家药监局签发的《药物临床试验批准通知书》，同意注射用顺铂聚合物胶束单药在晚期恶性肿瘤中开展临床试验。该药品为化药2.2类，旨在降低顺铂毒副作用并实现被动靶向性。目前国内尚无该药品获注册批件，公司提示研发及上市存在不确定性风险。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000032566.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660449641","title":"8月19日泰恩康跌5.02%，前海开源优质龙头6个月持有混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2660449641","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660449641?lang=zh_cn&edition=full","pubTime":"2026-08-19 17:16","pubTimestamp":1787130962,"startTime":"0","endTime":"0","summary":"证券之星消息，8月19日泰恩康跌5.02%，收盘报19.67元，换手率2.16%，成交量7.87万手，成交额1.58亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为前海开源基金的前海开源优质龙头6个月持有混合A。前海开源优质龙头6个月持有混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900029686.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660411584","title":"泰恩康H1净利降9成 A股募11.8亿国泰海通保荐拟发可转债","url":"https://stock-news.laohu8.com/highlight/detail?id=2660411584","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660411584?lang=zh_cn&edition=full","pubTime":"2026-08-19 11:32","pubTimestamp":1787110322,"startTime":"0","endTime":"0","summary":"中国经济网北京8月19日讯 泰恩康 近日披露2026年半年度报告。今年上半年，公司实现营业收入3.20亿元，同比下降7.72%；归属于上市公司股东的净利润为372.02万元，同比下降89.97%；归属于上市公司股东的扣非净利润为29.06万元，同比下降99.21%；经营活动产生的现金流量净额为5427.15万元，上年同期为-4037.98万元。 泰恩康本次发行费用总额为1.26亿元，其中保荐机构国泰君安证券获得保荐及承销费用1.02亿元。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202608/19/20260819574245.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202608/19/20260819574245.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260819/32339545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02827","601211","SABA","399300","BK0201","BK0250","03130","BK1564","301263","159982","BK0012","BK1147","FCEF","83188","BK0184","83130","BK0276","02611","82846","BK0183","07233","BK0188","02846","03188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660187264","title":"【机构调研记录】申万菱信基金调研泰恩康、盛美上海等3只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2660187264","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660187264?lang=zh_cn&edition=full","pubTime":"2026-08-19 08:14","pubTimestamp":1787098484,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及8月18日披露的机构调研信息，申万菱信基金近期对3家上市公司进行了调研，相关名单如下：1）泰恩康 调研纪要：MSCohi-O镜片2026年7月完成I期临床，进入IIa期，预计2027年完成IIb期后提交附条件上市申请。2）盛美上海 调研纪要：公司与海力士保持良好合作，相关进展达标后将披露。旗下最近一年表现最佳的公募基金产品为申万菱信智能驱动股票A，最新单位净值为10.03，近一年增长168.79%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900006988.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688082","BK0251","BK0250","301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660360466","title":"泰恩康：华创证券、国泰海通华源证券等多家机构于8月18日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2660360466","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660360466?lang=zh_cn&edition=full","pubTime":"2026-08-18 17:40","pubTimestamp":1787046058,"startTime":"0","endTime":"0","summary":"MSCohi-O镜片于 2023年 5月获 FD 孤儿药资格认定，成为全球第一款针对治疗眼部移植物抗宿主病被 FD认定孤儿药的药物。同时，无药物相关的严重不良反应发生，患者依从性高，显示优异的安全性。MSCohi-O 镜片现有适应症及后续拓展新适应症的合计销售峰值预计 15亿元以上。②预计盐酸毛果芸香碱滴眼液、利多卡因丙胺卡因气雾剂将于 2027年获批，有望实现快速放量，将成为公司重要增长动力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800031471.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0184","BK0012","BK0250","BK1147","BK0028","BK0276","601211","BK1564","BK0183","161027","02611","BK0201","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660346547","title":"泰恩康(301263)6月30日股东户数1.47万户，较上期增加12.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660346547","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660346547?lang=zh_cn&edition=full","pubTime":"2026-08-18 17:31","pubTimestamp":1787045492,"startTime":"0","endTime":"0","summary":"证券之星消息，近日泰恩康披露，截至2026年6月30日公司股东户数为1.47万户，较3月31日增加1680.0户，增幅为12.93%。在化学制药行业个股中，泰恩康股东户数低于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.64万户。从股价来看，2026年3月31日至2026年6月30日，泰恩康区间跌幅为4.66%，在此期间股东户数增加1680.0户，增幅为12.93%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800030787.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660463943","title":"泰恩康：公司正处于新旧动能转换的业绩拐点期","url":"https://stock-news.laohu8.com/highlight/detail?id=2660463943","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660463943?lang=zh_cn&edition=full","pubTime":"2026-08-18 16:54","pubTimestamp":1787043248,"startTime":"0","endTime":"0","summary":"证券之星消息，泰恩康08月18日在投资者关系平台上答复投资者关心的问题。泰恩康回复：尊敬的投资者朋友您好，针对您提出的问题回复如下：1、公司后续若拟召开业绩说明会将及时履行信息披露义务，请您留意公司在巨潮资讯网披露的相关公告。公司管理层将积极争取实现2026年股权激励的收入考核目标。感谢您对公司的关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800028962.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660431558","title":"图解泰恩康中报：第二季度单季净利润同比下降548.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660431558","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660431558?lang=zh_cn&edition=full","pubTime":"2026-08-18 01:31","pubTimestamp":1786987909,"startTime":"0","endTime":"0","summary":"证券之星消息，泰恩康2026年中报显示，上半年度公司主营收入3.2亿元，同比下降7.72%；归母净利润372.02万元，同比下降89.97%；扣非净利润29.06万元，同比下降99.21%；其中2026年第二季度，公司单季度主营收入1.31亿元，同比下降19.49%；单季度归母净利润-2486.27万元，同比下降548.88%；单季度扣非净利润-2745.34万元，同比下降606.23%；负债率32.35%，投资收益334.79万元，财务费用448.48万元，毛利率56.14%。财报数据概要请见下图:本文数据来源于泰恩康2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800001665.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660248284","title":"泰恩康：签署战略合作协议获MSCohi-O镜片项目独家商业推广权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2660248284","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660248284?lang=zh_cn&edition=full","pubTime":"2026-08-17 19:31","pubTimestamp":1786966277,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0250","301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658898237","title":"泰恩康（301263）披露全资子公司巴瑞替尼片中选第十二批国家药品集采，8月10日股价上涨1.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658898237","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658898237?lang=zh_cn&edition=full","pubTime":"2026-08-10 17:42","pubTimestamp":1786354962,"startTime":"0","endTime":"0","summary":"截至2026年8月10日收盘，泰恩康报收于21.75元，较前一交易日上涨1.64%，最新总市值为111.05亿元。该股当日开盘21.48元，最高22.58元，最低21.48元，成交额达1.52亿元，换手率为1.9%。近日，泰恩康发布《关于全资子公司部分药品中选国家药品集中采购的公告》。公告指出，中选后有望促进该产品销售放量和市场拓展，提升公司品牌影响力，对经营业绩产生积极影响；后续采购协议签订及业绩影响存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000023012.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658608631","title":"股市必读：泰恩康新发布《关于全资子公司部分药品中选国家药品集中采购的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2658608631","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658608631?lang=zh_cn&edition=full","pubTime":"2026-08-10 02:39","pubTimestamp":1786300750,"startTime":"0","endTime":"0","summary":"交易信息汇总资金流向8月7日主力资金净流出185.7万元，占总成交额1.02%；游资资金净流出303.09万元，占总成交额1.66%；散户资金净流入488.79万元，占总成交额2.67%。中选后有望促进该产品销售放量和市场拓展，提升公司品牌影响力，对经营业绩产生积极影响。后续采购协议签订及业绩影响存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000001140.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657161110","title":"泰恩康：全资子公司巴瑞替尼片中选第十二批国家药品集采","url":"https://stock-news.laohu8.com/highlight/detail?id=2657161110","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657161110?lang=zh_cn&edition=full","pubTime":"2026-08-07 17:42","pubTimestamp":1786095749,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657616195","title":"8月7日泰恩康涨6.31%，前海开源优质龙头6个月持有混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2657616195","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657616195?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:51","pubTimestamp":1786092660,"startTime":"0","endTime":"0","summary":"根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为前海开源基金的前海开源优质龙头6个月持有混合A。前海开源优质龙头6个月持有混合A目前规模为3.6亿元，最新净值0.6749，较上一交易日下跌1.08%，近一年下跌7.5%。前海开源优质龙头6个月持有混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700028243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656055733","title":"股市必读：泰恩康新发布《关于回购公司股份的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2656055733","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656055733?lang=zh_cn&edition=full","pubTime":"2026-08-04 01:36","pubTimestamp":1785778573,"startTime":"0","endTime":"0","summary":"截至2026年8月3日收盘，泰恩康报收于20.14元，下跌1.71%，换手率1.32%，成交量4.82万手，成交额9755.49万元。公司公告汇总：截至7月31日，泰恩康已累计回购股份2,434,400股，占总股本0.4768%，支付资金总额48,442,397.06元。公司公告汇总关于回购公司股份的进展公告广东泰恩康医药股份有限公司于2026年6月16日召开董事会，审议通过回购公司股份方案，拟使用自有及自筹资金以集中竞价方式回购A股股份，用于维护公司价值及股东权益。本次回购符合相关法规及公司方案规定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400001343.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652409681","title":"7月17日泰恩康跌11.14%，大成积极成长混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652409681","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652409681?lang=zh_cn&edition=full","pubTime":"2026-07-17 17:01","pubTimestamp":1784278871,"startTime":"0","endTime":"0","summary":"证券之星消息，7月17日泰恩康跌11.14%，收盘报19.3元，换手率2.95%，成交量10.76万手，成交额2.17亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为大成基金的大成积极成长混合A。大成积极成长混合A目前规模为9.3亿元，最新净值1.151，较上一交易日下跌1.37%，近一年上涨29.47%。大成积极成长混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030854.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652429360","title":"股市必读：泰恩康（301263）7月16日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2652429360","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652429360?lang=zh_cn&edition=full","pubTime":"2026-07-17 01:49","pubTimestamp":1784224149,"startTime":"0","endTime":"0","summary":"截至2026年7月16日收盘，泰恩康报收于21.72元，上涨3.92%，换手率2.78%，成交量10.14万手，成交额2.16亿元。董秘最新回复投资者： 截止目前最新股东人数？感谢您对泰恩康的关注！交易信息汇总资金流向7月16日主力资金净流入388.71万元；游资资金净流入534.0万元；散户资金净流出922.71万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700000972.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651645582","title":"7月15日泰恩康涨6.25%，大成积极成长混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651645582","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651645582?lang=zh_cn&edition=full","pubTime":"2026-07-15 16:37","pubTimestamp":1784104657,"startTime":"0","endTime":"0","summary":"证券之星消息，7月15日泰恩康涨6.25%，收盘报20.9元，换手率2.41%，成交量8.79万手，成交额1.82亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为大成基金的大成积极成长混合A。大成积极成长混合A目前规模为9.3亿元，最新净值1.191，较上一交易日上涨3.84%，近一年上涨34.58%。大成积极成长混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500031246.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649277376","title":"泰恩康（301263）披露控股股东部分股份解除质押公告，7月6日股价下跌1.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649277376","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649277376?lang=zh_cn&edition=full","pubTime":"2026-07-06 22:31","pubTimestamp":1783348277,"startTime":"0","endTime":"0","summary":"广东泰恩康医药股份有限公司于2026年7月6日发布公告，公司控股股东、实际控制人郑汉杰先生所持有的33,000,000股公司股份已于2026年7月3日办理了解除质押手续，占其所持股份比例的31.12%，占公司总股本的6.46%，质权人为北方国际信托股份有限公司。本次解除质押后，郑汉杰累计质押股份为21,620,000股，占其所持股份的20.39%。截至公告日，郑汉杰及其一致行动人孙伟文合计持有公司股份185,513,868股，累计质押股份50,294,000股，占合计持股的27.11%，占公司总股本的9.85%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600037660.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648164825","title":"7月1日泰恩康涨5.32%，大成积极成长混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2648164825","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648164825?lang=zh_cn&edition=full","pubTime":"2026-07-01 16:55","pubTimestamp":1782896140,"startTime":"0","endTime":"0","summary":"证券之星消息，7月1日泰恩康涨5.32%，收盘报21.58元，换手率3.47%，成交量12.64万手，成交额2.66亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为大成基金的大成积极成长混合A。大成积极成长混合A目前规模为9.3亿元，最新净值1.276，较上一交易日上涨2.16%，近一年上涨50.29%。大成积极成长混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100031776.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647554023","title":"泰恩康（301263）披露控股股东部分股份质押公告，6月30日股价下跌3.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647554023","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647554023?lang=zh_cn&edition=full","pubTime":"2026-06-30 22:16","pubTimestamp":1782828975,"startTime":"0","endTime":"0","summary":"截至2026年6月30日收盘，泰恩康报收于20.49元，较前一交易日下跌3.94%，最新总市值为104.62亿元。该股当日开盘21.0元，最高21.28元，最低20.12元，成交额达3.06亿元，换手率为4.09%。广东泰恩康医药股份有限公司于2026年6月30日发布公告，公司控股股东、实际控制人郑汉杰先生将其持有的11,500,000股公司股份质押给中原信托有限公司，占其所持股份比例10.84%，占公司总股本比例2.25%。郑汉杰本次质押后累计质押股份54,620,000股，占其所持股份51.50%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000046920.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787259396287,"stockEarnings":[{"period":"1week","weight":-0.0364},{"period":"1month","weight":0.0248},{"period":"3month","weight":-0.104},{"period":"6month","weight":-0.253},{"period":"1year","weight":-0.3426},{"period":"ytd","weight":-0.1775}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":0.0102},{"period":"3month","weight":-0.0509},{"period":"6month","weight":-0.0437},{"period":"1year","weight":0.0365},{"period":"ytd","weight":-0.0164}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"广东泰恩康医药股份有限公司","boardCode":"AI0051","boardName":"批发业","stockholders":"14676人(较上一季度增加12.93%)","perCapita":"24823股","listingDate":"2022-03-29","address":"广东省汕头市龙湖区泰山北路万吉南二街8号A幢","registeredCapital":"51059万元","survey":" 广东泰恩康医药股份有限公司的主营业务是代理运营及研发、生产、销售医药产品、医疗器械、卫生材料并提供医药技术服务与技术转让等。公司的主要产品是盐酸达泊西汀片、他达拉非片、枸橼酸西地那非口崩片、和胃整肠丸、沃丽汀、风油精、六味地黄丸、藿香正气丸、奥硝唑注射液。","listedPrice":19.93},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰恩康(301263)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰恩康(301263)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰恩康,301263,泰恩康股票,泰恩康股票老虎,泰恩康股票老虎国际,泰恩康行情,泰恩康股票行情,泰恩康股价,泰恩康股市,泰恩康股票价格,泰恩康股票交易,泰恩康股票购买,泰恩康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰恩康(301263)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰恩康(301263)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}